You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Neoplasms by Histologic Site

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

Esophageal Squamous Cell Carcinoma, Esophageal Tumors, Esophageal Diseases Trial (Anlotinib HCl, TQB2450)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • +10 more
  • (no location specified)
Feb 19, 2022

Prostatic Tumors, Castration-Resistant, Tumors by Histologic Type, Tumors, Prostate Trial in United States (P-PSMA-101 CAR-T

Active, not recruiting
  • Prostatic Neoplasms, Castration-Resistant
  • +16 more
  • Duarte, California
  • +9 more
Nov 15, 2022

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

Malignancy, Malignant Tumor, Lymphoproliferative Disorders Trial in United Kingdom (Atezolizumab)

Not yet recruiting
  • Malignancy
  • +8 more
  • Belfast, United Kingdom
  • +25 more
Mar 14, 2023

Solid Tumor, Haematological Malignancy, Malignancy Trial in United Kingdom (Entrectinib)

Recruiting
  • Solid Tumor
  • +10 more
  • Belfast, United Kingdom
  • +25 more
Mar 14, 2023

Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, Carcinoma, Squamous Cell Trial in Aarhus, Copenhagen, Odense (radiation,

Recruiting
  • Oropharynx Cancer
  • +18 more
  • Intensity-Modulated Radiation Therapy (IMRT)
  • +3 more
  • Aarhus, Denmark
  • +2 more
Sep 28, 2021

Solid Tumor, Haematological Malignancy, Malignant Tumor Trial in United Kingdom (Alectinib)

Recruiting
  • Solid Tumor
  • +10 more
  • Belfast, United Kingdom
  • +25 more
Mar 14, 2023

Pralsetinib to Best Available Therapy in RET-Fusion Positive

Enrolling by invitation
  • RET-fusion Non Small Cell Lung Cancer
  • +16 more
    • New York, New York
    • +2 more
    Aug 9, 2021

    Ovarian Tumors, Fallopian Tube Tumors, Tumors by Site Trial (Drug: Anlotinib, Drug: Carboplatin/Paclitaxel)

    Not yet recruiting
    • Ovarian Neoplasms
    • +14 more
    • Drug: Anlotinib
    • Drug: Carboplatin/Paclitaxel
    • (no location specified)
    Mar 17, 2021

    Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

    Recruiting
    • Lung Neoplasms
    • +23 more
    • La Jolla, California
    • +35 more
    Oct 6, 2022

    Spanish Series of Patients Treated With Radionuclide Lutetium177

    Recruiting
    • Neuroendocrine Tumors
    • +17 more
    • Lutetium [177Lu] oxodotreotide/dotatate
    • Santiago De Compostela, A Coruña, Spain
    • +18 more
    Jul 1, 2021

    Orelabrutinib in Combination With Standard Treatment Regimen for

    Not yet recruiting
    • Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type
    • Nanjing, Jiangsu, China
      Hematological Department, People's Hospital of Jiangsu Province
    Aug 23, 2023

    RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

    Active, not recruiting
    • RET-altered Non Small Cell Lung Cancer
    • +39 more
    • pralsetinib (BLU-667)
    • Phoenix, Arizona
    • +65 more
    Nov 10, 2022

    Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Tumors, Tumors by Site Trial in Nanjing (Anlotinib, Olaparib)

    Recruiting
    • Ovarian Cancer
    • +18 more
    • Nanjing, Jangsu, China
      JiangSu Cancer Hospital
    Oct 29, 2020

    Clinical, Radiological, Histologic and Molecular Features

    Recruiting
    • Meningeal Melanocytoma
    • +3 more
      • Nancy, France
        Nancy University Hospital Center
      Jul 31, 2023

      Ovarian Tumors, Fallopian Tube Tumors, Endocrine Gland Tumors Trial in Nanjing (Niraparib, Bevacizumab)

      Unknown status
      • Ovarian Neoplasms
      • +23 more
      • Nanjing, Jiangsu, China
        JiangSu Cancer Hospital
      Nov 8, 2020

      AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

      Not yet recruiting
      • AML
      • +11 more
      • (no location specified)
      Aug 14, 2023

      Respiratory Tract Diseases, Tumors, Tumors by Histologic Type Trial run by the National Cancer Institute (NCI) (Bevacizumab)

      Not yet recruiting
      • Respiratory Tract Diseases
      • +14 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Apr 10, 2023

      Glioma, Recurrence, Disease Attributes Trial (Vorasidenib)

      Available
      • Glioma
      • +10 more
      • (no location specified)
      Oct 19, 2022

      Tumors, Tumors, Glandular and Epithelial, Tumors by Histologic Type Trial in San Antonio (Entinostat, Placebo)

      Completed
      • Neoplasms
      • +14 more
      • San Antonio, Texas
        The START Center for Cancer Care
      Apr 21, 2022

      Glioblastoma, Glial Tumor, Brain Metastases Trial (CONVIVO system, Conventional histologic evaluation)

      Not yet recruiting
      • Glioblastoma
      • +5 more
      • CONVIVO system
      • Conventional histologic evaluation
      • (no location specified)
      Feb 9, 2022

      Salivary Gland Tumor, Diagnosis Trial in Thessaloníki (Fine Needle Aspiration, Histologic Examination)

      Completed
      • Salivary Gland Tumor
      • Diagnosis
      • Fine Needle Aspiration
      • Histologic Examination
      • Thessaloníki, Greece
        Aristotle University
      Sep 11, 2023

      Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Tumors Germ Cell and Embryonal Tumors by Histologic Type Tumors Tumors

      Not yet recruiting
      • Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms
      • HX008 + TACE
      • +2 more
      • Beijing, Beijing, China
        Beijing Cancer hospital
      Dec 8, 2022

      Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)

      Recruiting
      • Lymphoma
      • +7 more
      • ATLCAR.CD30 cells
      • Chapel Hill, North Carolina
        Lineberger Comprehensive Cancer Center at University of North Ca
      Dec 2, 2022